/MLPH

MLPH Stock - Molecular Pharmacology (USA), Ltd.

Q: What is the analyst price target for MLPH?

Analyst price target information is not currently available for MLPH.

Q: What is MLPH's market cap?

Market capitalization information is not currently available for MLPH.

Healthcare|Biotechnology|OTC

$0.00+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for MLPH

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2012

FY2013

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-7.35

52W High$0.00

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2013	FY2012
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-5,520	$-13,260	$-8,000	$-116,928	$-209,077
Net Income	$-5,520	$-901,260	$-8,000	$-116,928	$-209,900
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$0.00	$-0.00	$-0.00	$-0.00	$-0.00

Company Overview

Molecular Pharmacology (USA) Limited, a development stage company, develops and commercializes pain and inflammation management products primarily in Australia and the United States. The company, through its subsidiary, Molecular Pharmacology Pty. Ltd., develops analgesic and anti-inflammatory molecule, known as Tripeptofen for the treatment of common every-day pain. Its products are available in various dosage forms, formulations, line extensions, and package configurations. The company focuses on marketing its products through pharmaceutical distributors, and through collaborative dealings with companies in the United States and Europe. It also has an agreement with Dermatology Development Corporation to develop and market a range of therapeutic, cosmetic, and cosmecutical products based on the ThermaLIFE product range and its active ingredient. The company is based in Perth, Australia. Molecular Pharmacology (USA) Limited is a subsidiary of PharmaNet Group Limited.

Frequently Asked Questions about MLPH

What is MLPH's current stock price?

Molecular Pharmacology (USA), Ltd. (MLPH) is currently trading at $0.00 per share. The stock has moved +0.00% today.

What is the analyst price target for MLPH?

No analyst price targets are currently available for this stock.

What sector is Molecular Pharmacology (USA), Ltd. in?

Molecular Pharmacology (USA), Ltd. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.

What is MLPH's market cap?

Molecular Pharmacology (USA), Ltd. has a market capitalization of $0.00 billion, making it a small-cap company.

Does MLPH pay dividends?

No, Molecular Pharmacology (USA), Ltd. does not currently pay a dividend to shareholders.